The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development.
OpenCures is a platform for Self-Directed Research where individuals interested in gaining insight into their biomolecular health can measure biomarkers, share their protocols, samples, and data, and work with others to accelerate the development of cures for disease. OpenCures and has partnered with Bay Area Phlebotomy and Laboratory Services to give individuals access to research assays that can measure thousands of biomarkers and support them with educational tools and a platform to help them help themselves understand more about their health than ever before possible.
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, and biotechnology companies around the globe accelerate their research and drug development efforts. We create CRISPR genome edited model animals and cost-effective technologies to deliver insights into mechanism of action in vivo. Our experienced employees are focused on providing clients with data needed to make go/no-go decisions quickly and advance the discovery and early-stage development of new life extension therapies.
TAmiRNA is developing biofluid-based diagnostic tests based on circulating microRNAs and providing contract research services for discovery and validation of RNA-based biomarkers. The focus of TAmiRNA are age-associated diseases, where senescence plays a major role for onset and progression of disease. TAmiRNA has developed senomiR®, a proprietary microRNA signature intended for diagnosis of senescence burden and treatment response monitoring, and is looking to establish partnerships for development of disease/drug-specific applications of its biomarker platform.
Teneobio, Inc. is a clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAbs™). Our discovery platform comprises genetically engineered animals (UniRat®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. Versatile antibody variable domains are assembled into multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. Teneobio’s lead products are anti-CD3 T-cell engagers targeted against multiple tumor types, including TNB-383, currently in Phase I clinical trials for the treatment of Multiple Myeloma.
Gero is developing drugs against aging and aging-related diseases using next-generation AI technology.
Gero targets fundamental aging mechanisms and other aging-related conditions such as neurodegeneration accelerated aging/frailty after chemotherapy.
Gero managed to overcome limitations of previous generation AI by offering not just correlation analysis of biological big data, but causative models built with the use of physics of complex dynamic systems in addition to advanced machine learning.
The platform is extensively validated, enabling life extension and rejuvenation of multiple species. The Gero approach triggered multiple collaborations and publications with world top academics, including researchers from Harvard Medical School, MIT, NUS, Roswell Park Comprehensive Cancer Center. Gero is one investment round away from getting a proof of concept in humans, previous round investors are pharma professionals and AI entrepreneurs with exits to Facebook and Google.